Janssen Effect

Janssen Effect describes the phenomenon where early clinical trial outcomes appear highly favourable but later larger studies show reduced benefit due to initial small sample size, selection bias, or chance effects. This concept reflects the statistical tendency for extreme early results to regress towards the mean as more data accumulate. The term is used in clinical research interpretation to emphasise caution when evaluating early-phase efficacy signals.

The biopharmaceutical industry accounts for the Janssen effect when making development decisions based on limited early data. Phase I and Phase II studies may show strong responses in selected populations that do not replicate in broader Phase III trials. Programme teams incorporate adaptive designs, confirmatory cohorts, and robust statistical planning to reduce overestimation risk. Investors and stakeholders monitor early signals carefully, recognising uncertainty in small datasets. As development costs rise and programme failures become increasingly costly, understanding such statistical phenomena supports disciplined decision-making, realistic expectation-setting, and rigorous risk mitigation throughout clinical development.